The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab was able to increase weight by 5.6% at the ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

Cancer patients with wasting syndrome have gained weight after taking Pfizer’s anti-GDF-15 antibody in a midphase study, ...

Ponsegromab reached a clinically meaningful 5.6% mean weight increase at the high dose level in patients with cancer cachexia ...

As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...

The same set of clinical data on Cabometyx and Tecentriq in prostate cancer has led to two distinct regulatory plans between ...

"These results suggest cabozantinib should be a new treatment option for patients with previously treated extrapancreatic or pancreatic NETs." The study was also published simultaneously in the ...

Abbisko Therapeutics (HKEX: 02256) is excited to announce the receipt of the ESMO 2024 Best Poster Award on September 16, 2024. The award was received for the presentation titled "Updated Safety and ...

Trishula Therapeutics, Inc., a clinical stage, privately held biotechnology company, today reported final results from a ...

versus placebo in advanced pancreatic and extra-pancreatic neuroendocrine tumors (NETs)1,2 Data presented at ESMO 2024 and published in New England Journal of Medicine Ipsen has submitted an ...